Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 20 de 68
Filtrar
1.
J Periodontal Res ; 59(3): 552-564, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38193526

RESUMEN

OBJECTIVE: The present study aimed to evaluate the effects of reuterin, a bioactive isolated from the probiotic Lactobacillus reuteri (L. reuteri) on periodontal tissue regeneration, and provide a new strategy for periodontitis treatment in the future. BACKGROUND: Data discussing the present state of the field: Probiotics are essential for maintaining oral microecological balance. Our previous study confirmed that probiotic L. reuteri extracts could rescue the function of mesenchymal stem cells (MSCs) and promote soft tissue wound healing by neutralizing inflammatory Porphyromonas gingivalis-LPS. Periodontitis is a chronic inflammatory disease caused by bacteria seriously leading to tooth loss. In this study, we isolated and purified reuterin from an extract of L. reuteri to characterize from the extracts of L. reuteri to characterize its role in promoting periodontal tissue regeneration and controlling inflammation in periodontitis. METHODS: Chromatographic analysis was used to isolate and purify reuterin from an extract of L. reuteri, and HNMR was used to characterize its structure. The inflammatory cytokine TNFα was used to simulate the inflammatory environment. Periodontal ligament stem cells (PDLSCs) were treated with TNFα and reuterin after which their effects were characterized using scratch wound cell migration assays to determine the concentration of reuterin, an experimental periodontitis model in rats was used to investigate the function of reuterin in periodontal regeneration and inflammation control in vivo. Real-time PCR, dye transfer experiments, image analysis, alkaline phosphatase activity, Alizarin red staining, cell proliferation, RNA-sequencing and Western Blot assays were used to detect the function of PDLSCs. RESULTS: In vivo, local injection of reuterin promoted periodontal tissue regeneration of experimental periodontitis in rats and reduced local inflammatory response. Moreover, we found that TNFα stimulation caused endoplasmic reticulum (ER) stress in PDLSCs, which resulted in decreased osteogenic differentiation. Treatment with reuterin inhibited the ER stress state of PDLSCs caused by the inflammatory environment and restored the osteogenic differentiation and cell proliferation functions of inflammatory PDLSCs. Mechanistically, we found that reuterin restored the functions of inflammatory PDLSCs by inhibiting the intercellular transmission of ER stress mediated by Cx43 in inflammatory PDLSCs and regulated osteogenic differentiation capacity. CONCLUSION: Our findings identified reuterin isolated from extracts of the probiotic L. reuteri, which improves tissue regeneration and controls inflammation, thus providing a new therapeutic method for treating periodontitis.


Asunto(s)
Estrés del Retículo Endoplásmico , Gliceraldehído , Limosilactobacillus reuteri , Probióticos , Propano , Regeneración , Animales , Propano/análogos & derivados , Propano/farmacología , Propano/uso terapéutico , Probióticos/uso terapéutico , Probióticos/farmacología , Estrés del Retículo Endoplásmico/efectos de los fármacos , Gliceraldehído/análogos & derivados , Gliceraldehído/farmacología , Ratas , Regeneración/efectos de los fármacos , Periodontitis/microbiología , Ligamento Periodontal/efectos de los fármacos , Humanos , Masculino , Factor de Necrosis Tumoral alfa , Ratas Sprague-Dawley , Proliferación Celular/efectos de los fármacos , Células Madre/efectos de los fármacos
2.
Mol Carcinog ; 57(3): 347-360, 2018 03.
Artículo en Inglés | MEDLINE | ID: mdl-29073716

RESUMEN

Consumption of Brassica (Cruciferae) vegetables is associated with a reduced risk of cancer, but identification of the active components and insights into the underlying molecular events are scarce. Here we found that an extract of Lepidium latifolium, a cruciferous plant native to southern Europe, Mediterranean countries and Asia, showed in vitro cytotoxic activity, inducing caspase-dependent apoptosis, in a variety of human tumor cells, and the plant juice showed in vivo antitumor activity in a HT-29 human colon cancer xenograft mouse model. The epithionitrile 1-cyano-2,3-epithiopropane (CETP) was identified as the major active cancer cell-killing principle of L. latifolium. Synthetic and plant-derived CETP displayed similar proapoptotic activities as assessed by biochemical and morphological analyses. Analysis of the antiproliferative capacity of CETP on a wide number of cancer cell lines from the NCI-60 cell line panel followed by COMPARE analysis, showed an activity profile different from known anticancer agents. Flow cytometry and biochemical analyses revealed that CETP-induced apoptosis involved mitochondria, as assessed by loss of mitochondrial transmembrane potential and generation of reactive oxygen species, while overexpression of Bcl-XL and Bcl-2 prevented CETP-induced apoptosis. Inhibition of reactive oxygen species by glutathione and N-acetyl cysteine reduced the apoptotic response induced by CETP. FADD dominant negative form, blocking Fas/CD95 signaling, and a specific caspase-8 inhibitor also inhibited CETP-induced killing. Taken together, our data suggest that the cancer cell-killing action of CETP, involving both intrinsic and extrinsic apoptotic signaling pathways, underlies the antitumor activity of L. latifolium plant, which could be of potential interest in cancer treatment.


Asunto(s)
Antineoplásicos Fitogénicos/química , Antineoplásicos Fitogénicos/farmacología , Lepidium/química , Neoplasias/tratamiento farmacológico , Nitrilos/química , Nitrilos/farmacología , Propano/análogos & derivados , Compuestos de Sulfhidrilo/química , Compuestos de Sulfhidrilo/farmacología , Animales , Antineoplásicos Fitogénicos/uso terapéutico , Apoptosis/efectos de los fármacos , Línea Celular Tumoral , Femenino , Humanos , Potencial de la Membrana Mitocondrial/efectos de los fármacos , Ratones , Ratones SCID , Neoplasias/metabolismo , Neoplasias/patología , Nitrilos/uso terapéutico , Propano/química , Propano/farmacología , Propano/uso terapéutico , Especies Reactivas de Oxígeno/metabolismo , Transducción de Señal/efectos de los fármacos , Compuestos de Sulfhidrilo/uso terapéutico
3.
Infect Immun ; 85(10)2017 10.
Artículo en Inglés | MEDLINE | ID: mdl-28760934

RESUMEN

Integration of antibiotic and probiotic therapy has the potential to lessen the public health burden of antimicrobial-associated diseases. Clostridium difficile infection (CDI) represents an important example where the rational design of next-generation probiotics is being actively pursued to prevent disease recurrence. Because intrinsic resistance to clinically relevant antibiotics used to treat CDI (vancomycin, metronidazole, and fidaxomicin) is a desired trait in such probiotic species, we screened several bacteria and identified Lactobacillus reuteri to be a promising candidate for adjunct therapy. Human-derived L. reuteri bacteria convert glycerol to the broad-spectrum antimicrobial compound reuterin. When supplemented with glycerol, strains carrying the pocR gene locus were potent reuterin producers, with L. reuteri 17938 inhibiting C. difficile growth at a level on par with the level of growth inhibition by vancomycin. Targeted pocR mutations and complementation studies identified reuterin to be the precursor-induced antimicrobial agent. Pathophysiological relevance was demonstrated when the codelivery of L. reuteri with glycerol was effective against C. difficile colonization in complex human fecal microbial communities, whereas treatment with either glycerol or L. reuteri alone was ineffective. A global unbiased microbiome and metabolomics analysis independently confirmed that glycerol precursor delivery with L. reuteri elicited changes in the composition and function of the human microbial community that preferentially targets C. difficile outgrowth and toxicity, a finding consistent with glycerol fermentation and reuterin production. Antimicrobial resistance has thus been successfully exploited in the natural design of human microbiome evasion of C. difficile, and this method may provide a prototypic precursor-directed probiotic approach. Antibiotic resistance and substrate bioavailability may therefore represent critical new determinants of probiotic efficacy in clinical trials.


Asunto(s)
Antibacterianos/biosíntesis , Clostridioides difficile/crecimiento & desarrollo , Infecciones por Clostridium/prevención & control , Gliceraldehído/análogos & derivados , Glicerol/administración & dosificación , Limosilactobacillus reuteri/metabolismo , Probióticos , Propano/metabolismo , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Proteínas Bacterianas/genética , Clostridioides difficile/efectos de los fármacos , Infecciones por Clostridium/inmunología , Infecciones por Clostridium/terapia , Descubrimiento de Drogas/métodos , Farmacorresistencia Bacteriana , Heces/microbiología , Fermentación , Microbioma Gastrointestinal , Gliceraldehído/metabolismo , Gliceraldehído/farmacología , Gliceraldehído/uso terapéutico , Glicerol/inmunología , Glicerol/metabolismo , Humanos , Metabolómica , Propano/farmacología , Propano/uso terapéutico , Vancomicina/farmacología
4.
Oral Dis ; 23(4): 492-497, 2017 May.
Artículo en Inglés | MEDLINE | ID: mdl-28083982

RESUMEN

OBJECTIVE: Halitosis is caused by volatile sulphur compounds including methyl mercaptan (CH3 SH) in the oral cavity and is a serious problem that limits interpersonal social communication. The aim of study was to evaluate the effects of reuterin-related compounds (RRCs) on halitosis-related periodontopathic bacteria in vitro. MATERIALS AND METHODS: RRC-01, RRC-02 and RRC-03 (32 and 64 µg ml-1 ) in culture media containing Fusobacterium nucleatum JCM8523 and Porphyromonas gingivalis ATCC33277 were used. The effects of RRCs on CH3 SH production and detectable odour by F. nucleatum and P. gingivalis were examined by CH3 SH production assay and organoleptic test, respectively. The number of bacterial cells was also measured using an ATP assay. In P. gingivalis treated with RRCs, the expression of mgl gene, which is responsible for CH3 SH production, was examined by qRT-PCR. RESULTS: CH3 SH production and the score of detectable odour from F. nucleatum and P. gingivalis culture media containing RRCs were significantly lower than that without RRCs (P < 0.05). The expression of mgl gene in P. gingivalis was significantly downregulated by RRC-01 (P < 0.01), but not by RRC-02 or RRC-03. CONCLUSIONS: RRCs are potent oral care products for preventing halitosis via reducing CH3 SH production.


Asunto(s)
Antibacterianos/farmacología , Fusobacterium nucleatum/efectos de los fármacos , Gliceraldehído/análogos & derivados , Halitosis/microbiología , Odorantes/análisis , Porphyromonas gingivalis/efectos de los fármacos , Propano/farmacología , Antibacterianos/uso terapéutico , Biomarcadores/metabolismo , Fusobacterium nucleatum/metabolismo , Gliceraldehído/farmacología , Gliceraldehído/uso terapéutico , Halitosis/prevención & control , Humanos , Porphyromonas gingivalis/metabolismo , Propano/uso terapéutico , Compuestos de Sulfhidrilo/metabolismo
5.
Can J Physiol Pharmacol ; 91(2): 149-56, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-23458199

RESUMEN

Oxidative stress plays a key role in the progression of diabetes and its complications. In this study, the beneficial influence of the fungal metabolite nigerloxin, a new aldose reductase inhibitor and a free-radical scavenger, was investigated on oxidative stress in streptozotocin-induced diabetic rats. Groups of diabetic rats were orally administered nigerloxin for 30 days at a dose of 25 and 100 mg·(kg body mass)(-1)·day(-1). Diabetic rats showed significantly increased lipid peroxide levels in blood and liver, which was accompanied by lowered concentrations of antioxidant molecules and activities of antioxidant enzymes in blood and liver. Administration of nigerloxin for 30 days at a daily dose of 100 mg∙(kg body mass)(-1) to diabetic rats significantly decreased plasma and liver lipid peroxides, elevated the nonenzymatic antioxidants ascorbic acid, reduced glutathione, and total thiols, and elevated the activities of antioxidant enzymes in blood and liver. Nigerloxin showed a tendency to counter lipid abnormalities in diabetic animals, while fasting glucose and body mass were unaffected by nigerloxin treatment. Thus, this animal study has indicated the beneficial influence of nigerloxin on oxidative stress associated with diabetes that may have an implication in delaying or ameliorating the secondary complications.


Asunto(s)
Aldehído Reductasa/antagonistas & inhibidores , Aspergillus niger/metabolismo , Benzoatos/uso terapéutico , Diabetes Mellitus Experimental/tratamiento farmacológico , Depuradores de Radicales Libres/uso terapéutico , Estrés Oxidativo/efectos de los fármacos , Propano/análogos & derivados , Animales , Benzoatos/aislamiento & purificación , Diabetes Mellitus Experimental/enzimología , Diabetes Mellitus Experimental/metabolismo , Fermentación , Depuradores de Radicales Libres/aislamiento & purificación , Peróxidos Lipídicos/sangre , Peróxidos Lipídicos/metabolismo , Hígado/efectos de los fármacos , Hígado/enzimología , Masculino , Propano/aislamiento & purificación , Propano/uso terapéutico , Ratas , Ratas Wistar
6.
J Ayub Med Coll Abbottabad ; 35(3): 367-370, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-38404073

RESUMEN

BACKGROUND: To study the efficacy of a single 0.3ml of C3F8 injection for the treatment of symptomatic VMT. METHODS: In this retrospective interventional study a total of nine patients were recruited. The mean age was 67 years. Patients had a follow-up at one week and four weeks post injections. VMT status was confirmed on repeat Oct scan. RESULTS: There was a complete release of VMT In 4 patients after one week and further release of VMT was observed in two more patients after four weeks. Hence six out of nine patients had complete resolution of pathology following C3F8 injection. CONCLUSIONS: Intravitreal C3F8 is a cheaper and safer option for the treatment of vitreomacular traction as compared to pars plana vitrectomy or Ocriplasmin.


Asunto(s)
Propano , Perforaciones de la Retina , Humanos , Anciano , Propano/uso terapéutico , Perforaciones de la Retina/cirugía , Estudios Retrospectivos , Tracción , Inyecciones Intravítreas , Trastornos de la Visión , Tomografía de Coherencia Óptica
7.
Can J Physiol Pharmacol ; 90(4): 387-94, 2012 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-22423974

RESUMEN

Osmotic and oxidative stress have been implicated in the pathogenesis of diabetic cataract. Nigerloxin, a fungal metabolite, has been shown to possess aldose reductase inhibitory and free radical scavenging potential, in vitro. In the present study, the beneficial influence of nigerloxin was investigated on diabetes-induced alteration in the eye lens of rats treated with streptozotocin. Groups of diabetic rats were administered nigerloxin orally (100 mg·(kg body mass)(-1)·day(-1)) for 30 days. The activity of lens polyol pathway enzymes (aldose reductase and sorbitol dehydrogenase), lipid peroxides, and advanced glycation end products (AGEs) were increased in the diabetic animals. Levels of glutathione as well as the activity of antioxidant enzymes (superoxide dismutase, glutathione-S-transferase, and glutathione peroxidase) were decreased in the eye lens of the diabetic animals. The administration of nigerloxin significantly decreased levels of lipid peroxides and AGEs in the lens of the diabetic rats. Increase in the activity of aldose reductase and sorbitol dehydrogenase in the lens was countered by nigerloxin treatment. The activity of glutathione and antioxidant enzyme in the lens was significantly elevated in nigerloxin-treated diabetic rats. Examination of the treated rats' eyes indicated that nigerloxin delayed cataractogenesis in the diabetic rats. The results suggest the beneficial countering of polyol pathway enzymes and potentiation of the antioxidant defense system by nigerloxin in diabetic animals, implicating its potential in ameliorating cataracts in diabetics.


Asunto(s)
Benzoatos/uso terapéutico , Catarata/tratamiento farmacológico , Diabetes Mellitus Experimental/tratamiento farmacológico , Depuradores de Radicales Libres/uso terapéutico , Cristalino/efectos de los fármacos , Propano/análogos & derivados , Aldehído Reductasa/metabolismo , Animales , Antioxidantes/metabolismo , Benzoatos/farmacología , Catarata/inducido químicamente , Catarata/complicaciones , Catarata/metabolismo , Diabetes Mellitus Experimental/inducido químicamente , Diabetes Mellitus Experimental/complicaciones , Depuradores de Radicales Libres/farmacología , Glutatión/metabolismo , Productos Finales de Glicación Avanzada/metabolismo , L-Iditol 2-Deshidrogenasa/metabolismo , Cristalino/metabolismo , Peróxidos Lipídicos/metabolismo , Masculino , Propano/farmacología , Propano/uso terapéutico , Ratas , Ratas Wistar
8.
Nutrients ; 13(3)2021 Mar 22.
Artículo en Inglés | MEDLINE | ID: mdl-33809904

RESUMEN

The main biologically active components of plants belonging to the genus Allium, responsible for their biological activities, including anti-inflammatory, antioxidant and immunomodulatory, are organosulfur compounds. The aim of this study was to synthetize the mixture of dipropyl polysulfides (DPPS) and to test their biological activity in acute hepatitis. C57BL/6 mice were administered orally with DPPS 6 h before intravenous injection of Concanavalin A (ConA). Liver inflammation, necrosis and hepatocytes apoptosis were determined by histological analyses. Cytokines in liver tissue were determined by ELISA, expression of adhesive molecules and enzymes by RT PCR, while liver mononuclear cells were analyzed by flow cytometry. DPPS pretreatment significantly attenuated liver inflammation and injury, as evidenced by biochemical and histopathological observations. In DPPS-pretreated mice, messenger RNA levels of adhesion molecules and NADPH oxidase complex were significantly reduced, while the expression of SOD enzymes was enhanced. DPPS pretreatment decreased protein level of inflammatory cytokines and increased percentage of T regulatory cells in the livers of ConA mice. DPPS showed hepatoprotective effects in ConA-induced hepatitis, characterized by attenuation of inflammation and affection of Th17/Treg balance in favor of T regulatory cells and implicating potential therapeutic usage of DPPS mixture in inflammatory liver diseases.


Asunto(s)
Antiinflamatorios/uso terapéutico , Hepatitis/tratamiento farmacológico , Hígado/efectos de los fármacos , Propano/análogos & derivados , Sulfuros/uso terapéutico , Animales , Apoptosis , Concanavalina A , Modelos Animales de Enfermedad , Hepatitis/complicaciones , Hepatitis/patología , Hepatocitos/efectos de los fármacos , Hepatocitos/patología , Inflamación/etiología , Inflamación/prevención & control , Hígado/patología , Masculino , Ratones , Ratones Endogámicos C57BL , Necrosis , Propano/uso terapéutico
9.
J Med Chem ; 64(6): 3035-3047, 2021 03 25.
Artículo en Inglés | MEDLINE | ID: mdl-33666415

RESUMEN

3-Hydroxypropanamidines are a new promising class of highly active antiplasmodial agents. The most active compound 22 exhibited excellent antiplasmodial in vitro activity with nanomolar inhibition of chloroquine-sensitive and multidrug-resistant parasite strains ofPlasmodium falciparum (with IC50 values of 5 and 12 nM against 3D7 and Dd2 strains, respectively) as well as low cytotoxicity in human cells. In addition, 22 showed strong in vivo activity in thePlasmodium berghei mouse model with a cure rate of 66% at 50 mg/kg and a cure rate of 33% at 30 mg/kg in the Peters test after once daily oral administration for 4 consecutive days. A quick onset of action was indicated by the fast drug absorption shown in mice. The new lead compound was also characterized by a high barrier to resistance and inhibited the heme detoxification machinery in P. falciparum.


Asunto(s)
Amidinas/química , Amidinas/farmacología , Antimaláricos/química , Antimaláricos/farmacología , Malaria Falciparum/tratamiento farmacológico , Plasmodium falciparum/efectos de los fármacos , Amidinas/farmacocinética , Amidinas/uso terapéutico , Animales , Antimaláricos/farmacocinética , Antimaláricos/uso terapéutico , Línea Celular , Diseño de Fármacos , Humanos , Malaria/tratamiento farmacológico , Ratones , Pruebas de Sensibilidad Parasitaria , Plasmodium berghei/efectos de los fármacos , Propano/química , Propano/farmacocinética , Propano/farmacología , Propano/uso terapéutico
10.
N Engl J Med ; 356(23): 2349-60, 2007 Jun 07.
Artículo en Inglés | MEDLINE | ID: mdl-17554116

RESUMEN

BACKGROUND: Amyloid A (AA) amyloidosis is a complication of chronic inflammatory conditions that develops when proteolytic fragments of serum amyloid A protein (SAA) are deposited in tissues as amyloid fibrils. Amyloid deposition in the kidney causes progressive deterioration in renal function. Eprodisate is a member of a new class of compounds designed to interfere with interactions between amyloidogenic proteins and glycosaminoglycans and thereby inhibit polymerization of amyloid fibrils and deposition of the fibrils in tissues. METHODS: We performed a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of eprodisate in patients with AA amyloidosis and kidney involvement. We randomly assigned 183 patients from 27 centers to receive eprodisate or placebo for 24 months. The primary composite end point was an assessment of renal function or death. Disease was classified as worsened if any one of the following occurred: doubling of the serum creatinine level, reduction in creatinine clearance by 50% or more, progression to end-stage renal disease, or death. RESULTS: At 24 months, disease was worsened in 24 of 89 patients who received eprodisate (27%) and 38 of 94 patients given placebo (40%, P=0.06); the hazard ratio for worsening disease with eprodisate treatment was 0.58 (95% confidence interval, 0.37 to 0.93; P=0.02). The mean rates of decline in creatinine clearance were 10.9 and 15.6 ml per minute per 1.73 m(2) of body-surface area per year in the eprodisate and the placebo groups, respectively (P=0.02). The drug had no significant effect on progression to end-stage renal disease (hazard ratio, 0.54; P=0.20) or risk of death (hazard ratio, 0.95; P=0.94). The incidence of adverse events was similar in the two groups. CONCLUSIONS: Eprodisate slows the decline of renal function in AA amyloidosis. (ClinicalTrials.gov number, NCT00035334.)


Asunto(s)
Amiloidosis/tratamiento farmacológico , Glicosaminoglicanos/antagonistas & inhibidores , Enfermedades Renales/tratamiento farmacológico , Propano/análogos & derivados , Ácidos Sulfónicos/uso terapéutico , Amiloidosis/etiología , Amiloidosis/mortalidad , Artritis Reumatoide/complicaciones , Creatinina/sangre , Progresión de la Enfermedad , Método Doble Ciego , Fiebre Mediterránea Familiar/complicaciones , Femenino , Humanos , Estimación de Kaplan-Meier , Enfermedades Renales/etiología , Enfermedades Renales/mortalidad , Fallo Renal Crónico/prevención & control , Masculino , Persona de Mediana Edad , Propano/efectos adversos , Propano/uso terapéutico , Modelos de Riesgos Proporcionales , Proteinuria , Proteína Amiloide A Sérica/efectos de los fármacos , Ácidos Sulfónicos/efectos adversos
11.
Amyloid ; 14(2): 133-40, 2007 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-17577686

RESUMEN

OBJECTIVE: Amyloid A protein quantification in fat tissue is a new immunochemical method for detecting AA amyloidosis, a rare but serious disease. The objective was to assess diagnostic performance in clinical AA amyloidosis. METHODS: Abdominal subcutaneous fat tissue of patients with AA amyloidosis was studied at the start of an international clinical trial with eprodisate (NC-503; 1,3-propanedisulfonate; Kiacta), an antiamyloid compound. All patients had renal findings, i.e. proteinuria (> or =1 g/day) or reduced creatinine clearance (20 - 60 ml/min). Controls were patients with other types of amyloidosis and arthritic patients without amyloidosis. Amyloid A protein was quantified by ELISA using monoclonal antihuman serum amyloid A antibodies. Congo red stained slides were scored by light microscopy in a semiquantitative way (0 to 4+). RESULTS: Ample fat tissue (>50 mg) was available for analysis in 154 of 183 patients with AA amyloidosis and in 354 controls. The sensitivity of amyloid A protein quantification for detection of AA amyloidosis (>11.6 ng/mg fat tissue) was 84% (95% CI: 77 - 89%) and specificity 99% (95% CI: 98 - 100%). Amyloid A protein quantification and semiquantitative Congo red scoring were concordant. Men had lower amyloid A protein values than women (p < 0.0001) and patients with familial Mediterranean fever had lower values than patients with arthritis (p < 0.001) or other inflammatory diseases (p < 0.01). CONCLUSIONS: Amyloid A protein quantification in fat tissue is a sensitive and specific method for detection of clinical AA amyloidosis. Advantages are independence from staining quality and observer experience, direct confirmation of amyloid AA type, and potential for quantitative monitoring of tissue amyloid over time.


Asunto(s)
Grasa Abdominal/química , Amiloidosis/diagnóstico , Amiloidosis/metabolismo , Proteína Amiloide A Sérica/análisis , Adulto , Anciano , Anciano de 80 o más Años , Amiloidosis/clasificación , Amiloidosis/tratamiento farmacológico , Estudios de Casos y Controles , Rojo Congo , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Masculino , Persona de Mediana Edad , Propano/análogos & derivados , Propano/uso terapéutico , Ácidos Sulfónicos/uso terapéutico
12.
Oral Maxillofac Surg ; 21(1): 21-26, 2017 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-27873145

RESUMEN

PURPOSE: Keratocystic odontogenic tumor (KCOT) is an aggressive benign tumor and the management by complete enucleation followed by cryotherapy maintains the inorganic bone matrix, resulting in better repair and reduces the rates of recurrence. A refrigerant spray with a propane/butane/isobutane gas mixture has been pointed to as an alternative to liquid nitrogen, because the device is easy to handle and contain within the cavity, providing better control and lower risk of injury to the adjacent soft tissue. Thus, the aim of this study was to evaluate the outcome of enucleation followed by cryosurgery using a refrigerant spray of this gas mixture in ten patients diagnosed with KCOT. METHOD: The biggest lesions received a prior treatment consisting of marsupialization to decrease the tumor size. During the surgeries, the lesions were removed by enucleation and the surgical site was sprayed with the gas mixture. RESULTS: Wound dehiscence was observed in all cases, which healed by the second intention. The mean follow-up period was 64.3 months (range 24-120 months). Eight of the ten patients showed no evidence of clinical or radiographic recurrence. Pathologic fractures and infections were not observed. CONCLUSIONS: The results obtained suggest that enucleation followed by cryosurgery is an effective therapy for managing KCOT.


Asunto(s)
Butanos/uso terapéutico , Criocirugía/métodos , Neoplasias Mandibulares/cirugía , Quistes Odontogénicos/cirugía , Tumores Odontogénicos/cirugía , Propano/uso terapéutico , Adolescente , Adulto , Aerosoles , Niño , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos
13.
PLoS One ; 11(12): e0168092, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27977759

RESUMEN

Viscolin, an extract of Viscum coloratum, has anti-inflammatory and anti-proliferative properties against harmful stimuli. The aim of the study was to examine the anti-proliferative effects of viscolin on platelet derived growth factor-BB (PDGF)-treated human aortic smooth muscle cells (HASMCs) and identify the underlying mechanism responsible for these effects. Viscolin reduced the PDGF-BB-induced HASMC proliferation and migration in vitro; it also arrested HASMCs in the G0/G1 phase by decreasing the protein expression of Cyclin D1, CDK2, Cyclin E, CDK4, and p21Cip1 as detected by Western blot analysis. These effects may be mediated by reduced PDGF-induced phosphorylation of ERK1/2, JNK, and P38, but not AKT as well as inhibition of PDGF-mediated nuclear factor (NF)-κB p65 and activator protein 1 (AP-1)/c-fos activation. Furthermore, viscolin pre-treatment significantly reduced neointimal hyperplasia of an endothelial-denuded femoral artery in vivo. Taken together, viscolin attenuated PDGF-BB-induced HASMC proliferation in vitro and reduced neointimal hyperplasia in vivo. Thus, viscolin may represent a therapeutic candidate for the prevention and treatment of vascular proliferative diseases.


Asunto(s)
Compuestos de Bifenilo/farmacología , Compuestos de Bifenilo/uso terapéutico , Hiperplasia/tratamiento farmacológico , Miocitos del Músculo Liso/citología , Miocitos del Músculo Liso/efectos de los fármacos , Neointima/tratamiento farmacológico , Propano/análogos & derivados , Animales , Ciclo Celular/efectos de los fármacos , Ciclo Celular/genética , Movimiento Celular/efectos de los fármacos , Movimiento Celular/genética , Proliferación Celular/efectos de los fármacos , Proliferación Celular/genética , Células Cultivadas , Técnica del Anticuerpo Fluorescente , Humanos , Hiperplasia/metabolismo , Immunoblotting , Etiquetado Corte-Fin in Situ , Masculino , Ratones , Ratones Endogámicos C57BL , Miocitos del Músculo Liso/metabolismo , FN-kappa B/metabolismo , Neointima/metabolismo , Factor de Crecimiento Derivado de Plaquetas/farmacología , Propano/farmacología , Propano/uso terapéutico , Factor de Transcripción AP-1/metabolismo
16.
J Biomech ; 48(1): 122-9, 2015 Jan 02.
Artículo en Inglés | MEDLINE | ID: mdl-25468298

RESUMEN

Surface damage to articular cartilage is recognized as the initial underlying process causing the loss of mechanical function in early-stage osteoarthritis. In this study, we developed structure-modifying treatments to potentially prevent, stabilize or reverse the loss in mechanical function. Various polymers (chondroitin sulfate, carboxymethylcellulose, sodium hyaluronate) and photoinitiators (riboflavin, irgacure 2959) were applied to the surface of collagenase-degraded cartilage and crosslinked in situ using UV light irradiation. While matrix permeability and deformation significantly increased following collagenase-induced degradation of the superficial zone, resurfacing using tyramine-substituted sodium hyaluronate and riboflavin decreased both values to a level comparable to that of intact cartilage. Repetitive loading of resurfaced cartilage showed minimal variation in the mechanical response over a 7 day period. Cartilage resurfaced using a low concentration of riboflavin had viable cells in all zones while a higher concentration resulted in a thin layer of cell death in the uppermost superficial zone. Our approach to repair surface damage initiates a new therapeutic advance in the treatment of injured articular cartilage with potential benefits that include enhanced mechanical properties, reduced susceptibility to enzymatic degradation and reduced adhesion of macrophages.


Asunto(s)
Cartílago Articular/efectos de los fármacos , Sulfatos de Condroitina/uso terapéutico , Ácido Hialurónico/uso terapéutico , Osteoartritis/terapia , Riboflavina/uso terapéutico , Animales , Carboximetilcelulosa de Sodio/farmacología , Carboximetilcelulosa de Sodio/uso terapéutico , Cartílago Articular/efectos de la radiación , Bovinos , Muerte Celular , Supervivencia Celular/efectos de los fármacos , Supervivencia Celular/efectos de la radiación , Condrocitos/efectos de los fármacos , Condrocitos/efectos de la radiación , Sulfatos de Condroitina/farmacología , Colagenasas , Evaluación Preclínica de Medicamentos , Ácido Hialurónico/farmacología , Propano/análogos & derivados , Propano/farmacología , Propano/uso terapéutico , Riboflavina/química , Riboflavina/farmacología , Tiramina/química , Rayos Ultravioleta
17.
J Ethnopharmacol ; 172: 38-43, 2015 Aug 22.
Artículo en Inglés | MEDLINE | ID: mdl-26068427

RESUMEN

ETHNOPHARMACOLOGICAL RELEVANCE: Glycosmis pentaphylla (Retz.) Correa is used in Indian traditional medicine against various liver ailments, including cancer. AIM OF THE STUDY: Isolation and characterization of the most active anti-hepatocellular carcinoma (HCC) compound from the alcohol extract of G. pentaphylla. MATERIALS AND METHODS: Different chromatographic (HPLC, TLC and column chromatography) and methods like IR, LCMS and NMR were used for the isolation and structural identification of the active anti-HCC compound from G. pentaphylla. Cytotoxic and apoptosis inducing effect of the active compound were assessed in Hep3 B, RAW264.7 and HEK293 cell lines by MTT assay, morphological studies, Hoechst staining and Annexin V FITC assay. RESULTS: The most active compound was isolated as yellow needle shaped crystals. The structure of the compound was identified by IR, LCMS and NMR methods. The structural details show that the isolated compound is a novel chemical and have structural similarity with chalcone. MTT assay, physiological and FACS analysis proved the anti-HCC efficacy of the isolated compound in vitro. CONCLUSION: The study confirmed that the most active anti-HCC compound present in the alcohol extract of G. pentaphylla is a chalcone derivative. This compound showed specific cytotoxicity against Hep3 B with minor cytotoxicity against non HCC cell lines, RAW264.7 and HEK293. The present study, therefore, supports the folklore knowledge for the utility of G. pentaphylla and provides a scientific basis for their traditional usage against liver cancer.


Asunto(s)
Antineoplásicos Fitogénicos/farmacología , Antineoplásicos Fitogénicos/uso terapéutico , Carcinoma Hepatocelular/tratamiento farmacológico , Neoplasias Hepáticas/tratamiento farmacológico , Extractos Vegetales/farmacología , Extractos Vegetales/uso terapéutico , Propano/análogos & derivados , Pirroles/farmacología , Pirroles/uso terapéutico , Rutaceae/química , Animales , Antineoplásicos Fitogénicos/química , Antineoplásicos Fitogénicos/aislamiento & purificación , Apoptosis/efectos de los fármacos , Carcinoma Hepatocelular/patología , Línea Celular , Línea Celular Tumoral , Etanol/química , Humanos , Neoplasias Hepáticas/patología , Ratones , Estructura Molecular , Extractos Vegetales/química , Propano/química , Propano/farmacología , Propano/uso terapéutico , Pirroles/química
18.
Brain Res ; 1624: 469-478, 2015 Oct 22.
Artículo en Inglés | MEDLINE | ID: mdl-26315376

RESUMEN

We describe the sustained delivery of chondroitinase ABC (ChABC) in the hemisected spinal cord using polypropylene carbonate (PPC) electrospun fibers with chitosan (CS) microspheres as a vehicle. PPC and ChABC-loaded CS microspheres were mixed with acetonitrile, and micron fibers were generated by electrospinning. ChABC release was assessed in vitro with high-performance liquid chromatography (HPLC) and revealed stabilized and prolonged release. Moreover, the released ChABC showed sustained activity. PPC-CS micron fibers with or without ChABC were then implanted into a hemisected thoracic spinal cord. In the following 4 weeks, we examined functional recovery and performed immunohistochemical analyses. We found that sustained delivery of ChABC promoted axon sprouting and functional recovery and reduced glial scarring; PPC-CS micron fibers without ChABC did not show these effects. The present findings suggest that PPC-CS micron fibers containing ChABC are a feasible option for spinal cord injury treatment. Furthermore, the system described here may be useful for local delivery of other therapeutic agents.


Asunto(s)
Axones/efectos de los fármacos , Condroitina ABC Liasa/uso terapéutico , Recuperación de la Función/efectos de los fármacos , Regeneración/efectos de los fármacos , Traumatismos de la Médula Espinal/tratamiento farmacológico , Animales , Quitosano/uso terapéutico , Modelos Animales de Enfermedad , Conducta Exploratoria/efectos de los fármacos , Femenino , Regulación de la Expresión Génica/efectos de los fármacos , Actividad Motora/efectos de los fármacos , Proteínas del Tejido Nervioso/metabolismo , Propano/análogos & derivados , Propano/uso terapéutico , Ratas , Ratas Wistar , Estadísticas no Paramétricas , Factores de Tiempo
19.
J Alzheimers Dis ; 6(6 Suppl): S75-84, 2004 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-15665418

RESUMEN

GT 1061 is a novel therapeutic agent that is in Phase 1 clinical studies for Alzheimer's disease. GT 1061 is one of a family of novel nitrates that have demonstrated neuroprotective properties and cognition- and memory-enhancing properties in animal models. The prototype of this family, GT 715, has been reported effectively to dissociate the neuromodulatory and the systemic hypotensive effects of nitrates, the latter seriously limiting the therapeutic use of classical nitrates. Further data on the novel nitrates, GT 715 and GT 061, are presented in (a) the malonate-lesion rat model of excitotoxic neurodegeneration, and (b) the reversal of a scopolamine-induced cognition deficit in the Morris water task which tests spatial memory. These data exemplify and reinforce the combined neuroprotective and cognition enhancing properties observed in this family of NO mimetic therapeutic agents. NO mimetics, that mimic the biological activity of NO, will bypass cholinergic receptor activation and are anticipated to provide multiple pathways of treating and circumventing dementia. NO mimetic activation of soluble guanylyl cyclase and cGMP formation in the brain represents one element of an effective neuroprotective strategy. Substantial evidence suggests that NO mimetics may display cGMP-dependent and cGMP-independent activity and may operate via multiple biochemical signaling pathways, both to ensure the survival of neurons subjected to stress and also to provide cognition-enabling pathways to circumvent dementia, providing a combined neuroprotective and cognition-enabling approach to anti-neurodegenerative therapy.


Asunto(s)
Enfermedad de Alzheimer/tratamiento farmacológico , Materiales Biomiméticos/uso terapéutico , Fármacos Neuroprotectores/uso terapéutico , Nitratos/uso terapéutico , Óxido Nítrico/análogos & derivados , Óxido Nítrico/uso terapéutico , Propano/análogos & derivados , Enfermedad de Alzheimer/patología , Animales , Conducta Animal/efectos de los fármacos , Encéfalo/efectos de los fármacos , Encéfalo/patología , Proteínas Portadoras/biosíntesis , Supervivencia Celular/efectos de los fármacos , Trastornos del Conocimiento/inducido químicamente , Trastornos del Conocimiento/tratamiento farmacológico , Péptidos y Proteínas de Señalización Intracelular , Masculino , Trastornos de la Memoria/inducido químicamente , Trastornos de la Memoria/tratamiento farmacológico , Antagonistas Muscarínicos/administración & dosificación , Antagonistas Muscarínicos/efectos adversos , Neuronas/efectos de los fármacos , Neuronas/patología , Fármacos Neuroprotectores/farmacología , Nitratos/farmacología , Propano/farmacología , Propano/uso terapéutico , Ratas , Ratas Sprague-Dawley , Escopolamina/administración & dosificación , Escopolamina/efectos adversos , Transducción de Señal/efectos de los fármacos , Percepción Espacial/efectos de los fármacos , Conducta Espacial/efectos de los fármacos
20.
Neurosci Lett ; 352(2): 117-20, 2003 Dec 04.
Artículo en Inglés | MEDLINE | ID: mdl-14625037

RESUMEN

The aim of the study is to establish if the putative anticonvulsant SPM 927 has an analgesic effect in human neuropathic pain and to assess its tolerability. This is an open label study of 25 adult human subjects with resistant neuropathic pain. Subjects were treated with SPM 927 in a dose-escalating scheme to 600 mg daily, if tolerated. Treatment was continued for 4 weeks then withdrawn without tapering. Pain scores were recorded using a 11-point Likert score and a categorical pain-rating scale. Laboratory parameters and, electrocardiographs (ECGs) were collected; side effects were noted. Of the 25 enrolled subjects, 12 completed the study according to the protocol. The remaining subjects dropped out due to adverse events (n=12) or withdrawn consent. Mean daily pain scores (Likert score) fell by 0.83 (95% CI -1.77, +0.11) at the end of maintenance and rose by 0.58 (95% CI -0.23, +1.40) after withdrawal of SPM 927. Similar changes were seen in the categorical pain-rating scores. There were decreases in the mean scores for shooting pain, paraesthesia, and allodynia, but much less change in the numbness and burning-pain scores. The most common side effects were nausea, dizziness, leukocytosis, and increased ALT. No consistent changes in ECG recordings or haemodynamic variables were observed. SPM 927 may have an analgesic effect in human neuropathic pain and was reasonably well tolerated in this study. These data support the continued clinical development of SPM 927 for neuropathic pain.


Asunto(s)
Amidas/uso terapéutico , Analgésicos/uso terapéutico , Mononeuropatías/tratamiento farmacológico , Dolor/tratamiento farmacológico , Propano/análogos & derivados , Propano/uso terapéutico , Adulto , Intervalos de Confianza , Femenino , Humanos , Masculino , Persona de Mediana Edad , Mononeuropatías/fisiopatología , Dolor/fisiopatología
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda